Multiple Sclerosis Market to Reach USD 30.6 Billion by 2034 at 3.80% CAGR Across the 7MM | DelveInsight

DelveInsight's "Multiple Sclerosis Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of MS, historical and forecasted epidemiology, as well as the MS market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Explore the intricate details of the Multiple Sclerosis Market Report @ https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Multiple Sclerosis Market Report
• The Multiple Sclerosis market in the 7MM was valued at USD 21,831 million in 2025 and is projected to reach USD 30,597 million by 2034, growing at a CAGR of 3.80% over the forecast period (2025-2034).
• The Multiple Sclerosis Market Size in the US was approximately USD 16,000 million in 2024 and is anticipated to increase due to the launch of emerging therapies.
• DelveInsight estimates that there were approximately 1,655 thousand Multiple Sclerosis Prevalent Cases across the 7MM in 2024, projected to rise at a CAGR of 1.5% during the forecast period (2025-2034).
• In 2024, approximately 920 thousand adults in the US were living with a Multiple Sclerosis diagnosed prevalent case, a number projected to rise by 2034.
• Among EU4 and the UK, Germany had the highest number of MS diagnosed prevalent cases in 2024, with approximately 255 thousand cases, while Spain had the lowest, with around 65 thousand cases.
• As of 2024, relapsing-remitting MS (RRMS) was the most widespread form across EU4 and the UK, affecting approximately 490 thousand individuals, followed by secondary progressive MS (SPMS) with about 110 thousand cases and primary progressive MS (PPMS) with around 90 thousand cases.
• In Japan, MS continues to show a marked gender disparity, with females accounting for approximately 69% of cases and males 31%.
• The Multiple Sclerosis Companies include Roche, Sanofi, Novartis, AB Science, Clene Nanomedicine, InnoCare Pharma, and others.
• Promising Multiple Sclerosis Therapies include remibrutinib, tolebrutinib, fenebrutinib, frexalimab, vidofludimus calcium, CNM-Au8, masitinib, among others.

Get a Free sample for the Multiple Sclerosis Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Recent Developments in the Multiple Sclerosis Market
• In May 2026, Cantex Pharmaceuticals and Headlamp Health forged a strategic partnership to accelerate the development of azeliragon using agentic precision neuropsychiatry, leveraging Headlamp's AI data platform to identify and stratify MS patients suffering from severe depression and fatigue linked to chronic brain inflammation.
• In August 2025, Hope Biosciences received FDA RMAT designation for its HB-adMSCs stem cell therapy for treating relapsing-remitting multiple sclerosis (RRMS).
• In May 2025, Neuralink announced it received the FDA's "breakthrough" designation for its device aimed at restoring communication for individuals with severe speech impairment, including patients with conditions like ALS, stroke, spinal cord injury, cerebral palsy, and multiple sclerosis.
• In April 2025, NEJM published findings from the Phase III GEMINI 1 and 2 studies evaluating tolebrutinib in patients with RMS; these data were also featured in the Clinical Trials Plenary Session at AAN 2025.

What is Multiple Sclerosis?
MS is a lifelong, unpredictable disease that affects each person differently. While a small group experiences a mild form with little disability, others face a steadily worsening condition that leads to significant limitations. Most people go through cycles of symptom flare-ups such as vision problems, muscle weakness, or numbness followed by periods of recovery. Women are more often affected than men. Though MS is rarely fatal and many live long, full lives, the disease can take a heavy toll, especially without early treatment. Initial signs often include blurred or double vision, eye pain from optic neuritis, or weakness and stiffness in the arms or legs, sometimes accompanied by painful muscle spasms. People may also feel tingling or numbness, have trouble with balance, or struggle with bladder issues. Over time, fatigue can become overwhelming, and mental health may suffer, with mood swings, depression, or trouble thinking clearly.

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ https://www.delveinsight.com/report-store/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Multiple Sclerosis Epidemiology Segmentation in the 7MM
• Total Multiple Sclerosis Diagnosed Prevalent Cases
• Multiple Sclerosis Gender-specific Diagnosed Prevalent Cases
• Multiple Sclerosis Phenotype-specific Diagnosed Prevalent Cases
• Multiple Sclerosis EDSS-specific Diagnosed Prevalent Cases

Multiple Sclerosis Marketed Drugs
• OCREVUS (ocrelizumab): Roche (Genentech)
OCREVUS is a humanized monoclonal antibody designed to target CD20-positive B cells implicated in driving inflammation and damage to myelin and nerve fibers in MS. It selectively binds to CD20-expressing B cells while sparing stem cells and plasma cells. Administered IV, it is available as a 300 mg/10 mL solution in a single-use vial. In March 2017, the US FDA approved OCREVUS for both relapsing forms of MS (RMS) and PPMS, making it the first therapy specifically approved for PPMS.

• OCREVUS ZUNOVO (ocrelizumab and hyaluronidase-ocsq): F. Hoffmann-La Roche (Genentech)
OCREVUS ZUNOVO is a subcutaneous formulation of ocrelizumab enhanced by ENHANZE technology using hyaluronidase (rHuPH20) to increase tissue permeability and speed absorption. Administered as a 920 mg injection every six months over 10 minutes, it offers a convenient alternative to IV infusion. In September 2024, the US FDA approved it as the first and only SC treatment for both relapsing and progressive MS.

• LEMTRADA (alemtuzumab): Sanofi
LEMTRADA is a cytolytic monoclonal antibody targeting CD52, approved for relapsing forms of MS, including active secondary progressive MS, in individuals aged 17 and older. Due to significant safety risks, it is generally reserved for patients who have failed at least two prior MS treatments and is accessible only through the LEMTRADA REMS Program. The US FDA approved LEMTRADA in November 2014.

Multiple Sclerosis Emerging Drugs
• Tolebrutinib (SAR442168): Sanofi
An investigational oral BTK inhibitor designed to cross the blood-brain barrier and target smoldering neuroinflammation, a key driver of disability progression in MS. In March 2025, the US FDA accepted tolebrutinib for priority review for non-relapsing secondary progressive MS (nrSPMS), with a decision expected by September 2025.

• Fenebrutinib: Roche (Genentech)
An investigational oral BTK inhibitor with reversible, non-covalent binding, targeting both B cells and microglia. It is the sole reversible BTK inhibitor in Phase III trials for MS, evaluated in FENhance 1 and 2 (relapsing MS) and FENtrepid, which compares it head-to-head with ocrelizumab in primary progressive MS.

• Remibrutinib: Novartis
An investigational, highly selective covalent BTK inhibitor currently in Phase III REMODEL-1 and REMODEL-2 trials, with primary completion data expected in 2026 and regulatory filing in 2027.

Multiple Sclerosis Companies
Roche, Sanofi, Novartis, AB Science, Clene Nanomedicine, InnoCare Pharma, and others

Discover more about therapies set to grab major Multiple Sclerosis market share @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Multiple Sclerosis Market Outlook
MS is the most common primary demyelinating disorder of the central nervous system, characterized by progressive neurological decline. While its exact cause remains unclear, it is believed to involve an autoimmune response against myelin triggered by autoreactive T and B cells that breach the blood-brain barrier, leading to demyelination, axonal damage, and neurodegeneration. Acute relapses are typically managed with intravenous corticosteroids like methylprednisolone followed by oral tapering, though these do not impact long-term progression. Long-term management centers on disease-modifying therapies (DMTs) that aim to reduce relapse rates and slow progression.

OCREVUS (ocrelizumab) by Genentech/Roche remains a cornerstone therapy, approved for relapsing forms and PPMS, for which it remains the only approved therapy. OCREVUS ZUNOVO introduces a subcutaneous formulation for added convenience. Sanofi's LEMTRADA is indicated for RRMS and active SPMS. The growing use of oral agents like MAYZENT (siponimod), VUMERITY (diroximel fumarate), and MAVENCLAD (cladribine) marks a shift toward more convenient, patient-centric treatment options. Among interferon-based therapies, PLEGRIDY offers dosing every two to four weeks, while S1P receptor modulators ZEPOSIA and PONVORY offer once-daily oral dosing. CD20-directed therapies such as KESIMPTA and BRIUMVI reflect a shift toward high-efficacy B-cell depletion strategies.

The Multiple Sclerosis market in the 7MM was valued at USD 21,831 million in 2025 and is projected to reach USD 30,597 million by 2034 at a CAGR of 3.80%. The US Market Size was approximately USD 16,000 million in 2024, while EU4 and the UK combined were calculated at approximately USD 4,000 million in 2024, nearly 20% of 7MM revenue. Among EU4 and the UK, Germany dominated in 2024 with around USD 1,550 million, followed by the UK at approximately USD 850 million and Italy at around USD 700 million. Japan's Multiple Sclerosis Market Size was approximately USD 230 million in 2024, anticipated to increase over the forecast period.

Scope of the Multiple Sclerosis Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM (US, EU4, UK, and Japan)
• Multiple Sclerosis Companies: Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, and others
• Multiple Sclerosis Therapies: OCREVUS, OCREVUS ZUNOVO, LEMTRADA, and others
• Multiple Sclerosis Epidemiology: Total Diagnosed Prevalent Cases, Gender-specific, Phenotype-specific, and EDSS-specific Diagnosed Prevalent Cases
• Multiple Sclerosis Market Analysis: KOL Views, Attribute Analysis, SWOT Analysis, Unmet Needs

To know more about Multiple Sclerosis companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Multiple Sclerosis Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Multiple Sclerosis Epidemiology and Market Methodology
8. Multiple Sclerosis Epidemiology and Patient Population
9. Multiple Sclerosis Patient Journey
10. Multiple Sclerosis Marketed Drugs
11. Multiple Sclerosis Emerging Drug Profiles
12. Multiple Sclerosis Market Analysis
13. Key Opinion Leaders' Views
14. Multiple Sclerosis Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.